Physician
Narayan, Anand
Narayan, Anand was paid $527K by Medicaid between Nov 2020 and Jan 2022, across 42 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 47% of everything it billed.
33Billing provider infoNARAYAN, ANAND
DINUBA, CA 93618
DINUBA, CA 93618
33aNPI1013221845assigned 08/04/2010
33bProvider typeEmergency Medicine Physician
28Total paid$527K
24GClaims29,079
24DCodes billed42
24AFirst – last monthNov 2020 – Jan 2022
Compared with peers
Next to other Emergency Medicine Physician providers in California
Rank by total paid#259 of 988
Median peer was paid$32K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,403 | $24K | |
| 2021 | 22,664 | $404K | |
| 2022 | 5,012 | $99K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 47% | 11,675 | 9,235 | $246K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 2,418 | 2,236 | $71K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 6.4% | 1,076 | 1,071 | $34K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.6% | 1,848 | 1,697 | $29K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.1% | 311 | 311 | $22K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.0% | 205 | 205 | $21K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.0% | 493 | 469 | $21K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.8% | 1,187 | 1,185 | $20K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.5% | 254 | 253 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.3% | 1,780 | 1,516 | $17K |
| J3490 | Unclassified drugs | 2.8% | 204 | 204 | $15K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.2% | 182 | 182 | $6K |
30 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 60 | $3K |
| 87428 | <1% | 558 | $645.13 | |
| 92552 | <1% | 641 | $435.63 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 156 | $149.46 |
| 90686 | <1% | 542 | $137.18 | |
| 85018 | <1% | 1,058 | $91.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 195 | $84.59 |
| 99173 | <1% | 643 | $67.47 | |
| 81003 | <1% | 989 | $64.25 | |
| 81025 | <1% | 469 | $44.10 | |
| D1206 | Topical application of fluoride varnish | <1% | 227 | $35.64 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 258 | $35.46 |
| 90700 | <1% | 110 | $30.70 | |
| 93000 | <1% | 38 | $28.41 | |
| 86580 | <1% | 585 | $23.00 | |
| 90707 | <1% | 86 | $9.00 | |
| 90715 | <1% | 91 | $9.00 | |
| 90734 | <1% | 93 | $9.00 | |
| 90670 | <1% | 69 | $9.00 | |
| 90648 | <1% | 83 | $9.00 | |
| 90713 | <1% | 35 | $9.00 | |
| 90651 | <1% | 134 | $9.00 | |
| 90716 | <1% | 86 | $9.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 58 | $6.29 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $0.56 |
| 90633 | 0% | 66 | $0.00 | |
| 90620 | 0% | 45 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 18 | $0.00 |
| 90688 | 0% | 25 | $0.00 | |
| 90723 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.